Amgen Valuation

Amgen Inc -- USA Stock  

USD 188.01  1.27  0.67%

Amgen Inc shows prevailing Real Value of $159.6001 per share. The current price of the firm is $188.01. At this time the firm appears to be over valued. Macroaxis approximates value of Amgen Inc from analyzing the firm fundamentals such as Profit Margin of 35.54% and Return On Equity of 25.96% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Valuation Drivers Correlation

Selected Amgen Inc Valuation Data Over Time

Net Income Per Employee    Enterprise Value    Market Capitalization    
 Time Horizon     30 Days    Login   to change
Amgen Inc is rated third in price to earning category among related companies. It is number one stock in beta category among related companies totaling about  0.1  of Beta per Price to Earning. The ratio of Price to Earning to Beta for Amgen Inc is roughly  10.11 
Over Valued
January 20, 2018
Market Value
Downside upside
Real Value
Target Price Odds
 Above  Below  
Upside upside
Amgen is not too risky asset. Calculation of real value of Amgen Inc is based on 1 month time horizon. Increasing Amgen Inc time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.


Amgen Analyst Recommendations
Target PriceAdvice# of Analysts
Amgen Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Amgen Analyst Advice  

Tax Efficiency

Amgen Inc Tax Efficiency History

Tax Efficiency

Market Capitalization

Amgen Market Capitalization Analysis
Amgen Inc is number one stock in market capitalization category among related companies. Market capitalization of Pharmaceuticals And Biosciences industry is presently estimated at about 348.23 Billion. Amgen totals roughly 136.48 Billion in market capitalization claiming about 39% of equities listed under Pharmaceuticals And Biosciences industry.
Capitalization  Workforce  Valuation  Total debt  Revenue


Amgen Inc Revenue
Based on latest financial disclosure Amgen Inc reported 23.01 B of revenue. This is 254.0% higher than that of the Healthcare sector, and significantly higher than that of Pharmaceuticals And Biosciences industry, The Revenue for all stocks is 133.68% lower than the firm.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can includes product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.